Bristol Myers Squibb Stock Current Asset
| BMY Stock | USD 57.88 2.05 3.67% |
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Stock. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers stock.
Non Current Assets Total is likely to rise to about 66 B in 2025. Other Current Assets is likely to rise to about 5.9 B in 2025. Bristol | Current Asset |
Bristol Myers Squibb Company Current Asset Analysis
Bristol Myers' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Bristol Myers Current Asset | 10.41 B |
Most of Bristol Myers' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bristol Current Asset Historical Pattern
Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bristol Myers current asset as a starting point in their analysis.
Bristol Myers Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Bristol Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Bristol Myers Squibb has a Current Asset of 10.41 B. This is 383.99% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current asset for all United States stocks is 11.53% lower than that of the firm.
Bristol Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in current asset category among its peers.
Bristol Myers ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.Environmental | Governance | Social |
Bristol Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | 0.0655 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 157.8 B | ||||
| Shares Outstanding | 2.03 B | ||||
| Shares Owned By Insiders | 0.33 % | ||||
| Shares Owned By Institutions | 80.71 % | ||||
| Number Of Shares Shorted | 26.7 M | ||||
| Price To Earning | 24.88 X | ||||
| Price To Book | 7.19 X | ||||
| Price To Sales | 2.45 X | ||||
| Revenue | 48.3 B | ||||
| Gross Profit | 36.35 B | ||||
| EBITDA | 3.17 B | ||||
| Net Income | (8.93 B) | ||||
| Cash And Equivalents | 9.12 B | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 51.2 B | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 8.05 X | ||||
| Cash Flow From Operations | 15.19 B | ||||
| Short Ratio | 2.78 X | ||||
| Earnings Per Share | (4.41) X | ||||
| Price To Earnings To Growth | 1.31 X | ||||
| Target Price | 61.34 | ||||
| Number Of Employees | 34.1 K | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 118.13 B | ||||
| Total Asset | 92.6 B | ||||
| Retained Earnings | 14.91 B | ||||
| Working Capital | 6.01 B | ||||
| Current Asset | 10.41 B | ||||
| Current Liabilities | 8.02 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 2.96 % | ||||
| Net Asset | 92.6 B | ||||
| Last Dividend Paid | 2.42 |
About Bristol Myers Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.